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CLINICAL OBSERVATIONS IN HEPATOLOGY
Raised Serum Ferritin Concentration in Hereditary
Hyperferritinemia Cataract Syndrome Is Not a Marker
for Iron Overload
Dan Yin,1,2 Vasu Kulhalli,3 and Ann P. Walker2
Hyperferritinemia and bilateral cataracts are features of the rare hereditary hyperferriti-
nemia cataract syndrome (HHCS; OMIM #600886). HHCS is an autosomal dominant
condition caused by mutations which increase expression of the ferritin light polypep-
tide (FTL) gene. We report a patient with HHCS who was misdiagnosed and treated as
having hemochromatosis, in whom a heterozygous c.-160A>G mutation was identified
in the iron responsive element (IRE) of FTL, causing ferritin synthesis in the absence of
iron overload. This report demonstrates the need for clinical awareness of HHCS as a
cause of hyperferritinemia in the absence of iron overload and provides a possible
diagnostic schema. (HEPATOLOGY 2014;59:1204-1206)
Case Report
A 43-year-old Caucasian man was hospitalized fol-
lowing exposure to formaldehyde. His hemoglo bin,
serum iron concentration, total iron binding capacity
(TIBC), and transferrin saturation were within the lab-
oratory reference ranges but his serum ferritin concen-
tration was elevated (1650 lg/L; reference range 25-
300 lg/L). Serum transaminase activities, copper, ceru-
loplasmin, and lead concentrations were normal. A
liver biopsy showed normal liver architecture and no
evidence of iron overload. There was no history of
alcohol abuse. He did, however, have a family history
of hemochromatosis in a pattern suggestive of autoso-
mal dominant inheritance (Fig. 1A) and a personal
history of bilateral rheumatoid factor negative arthritis
affecting his ankles and knees which had resolved
spontaneously after 6 months and of bilateral cataract
removal the previous year. A diagnosis of hemochro-
matosis was made on the basis of the strong family
history and the presence of persistent hyperferritinemia
despite the absence of evidence of iron overload. Vene-
section (450 mL) was performed monthly for 6
months but was stopped when the patient became
symptomatic with a microcytic, iron deficient anemia
in the absence of any other source of bleeding; at this
time his hemoglobin was 10.0 g/dL (12.5-17.5 g/dL),
transferrin saturation 4% (20%-55%) while his serum
ferritin remained elevated at 1,728 lg/L. Venesection
was stopped; he was treated with iron supplements
until he was iron replete; his serum ferritin concentra-
tions remained elevated throughout.
HFE mutation screening for p.(C282Y) and
p.(H63D) showed that the patient was p.(H63D) het-
erozygous. This genotype is unlikely to be associated
with HFE-hemochromatosis. Ferroportin (SLC40A1)
coding and splice site sequence was wild-type.1 A het-
erozygous c.-160A>G mutation was identified in the
IRE within the 50 untranslated region (50-UTR) of
FTL, in the patient and his mother (Fig 1B). Bioinfor-
matic analysis (http://ccbg.imppc.org/sires/index.html)
predicted that the mutant messenger RNA (mRNA)
will not form the regulatory IRE “hairpin” structure
(Fig 1C). These results confirmed a diagnosis of
HHCS. Subsequent investigation showed that the
inheritance of hyperferritinemia in this family
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coincided with the inheritance of bilateral cataracts
(Fig. 1A).
Within cells, ferritin is comprised of 24 FTL and
ferritin heavy polypeptide 1 (FTH1) subunits, forming
a hollow sphere within which excess iron can be stored
safely. When intracellular iron concentrations are low
the requirement for iron storage is also low; iron
responsive proteins (IRPs) bind IREs and so decrease
translation of ferritin subunits. In HHCS, the IRE
mutation reduces IRP binding and impairs the normal
suppression of FTL translation at low intracellular iron
concentrations, so serum ferritin concentrations are
elevated in the absence of iron loading (Fig 1D).
Discussion
Serum ferritin concentration, in the absence of poten-
tial confounding factors such as inflammation, obesity,
and cancer, is an indicator of body iron stores. Despite
its widespread use as a clinical marker, the origins of
serum ferritin remain incompletely understood. Serum
ferritin mainly comprises truncated FTL subunits and
surprisingly contains little iron, so it differs from intra-
cellular ferritin. Serum ferritin is thought to be mainly
secreted by macrophages, although hepatocytes and other
cells may also contribute.2 In HHCS, L-ferritin synthesis
is uncoupled from cellular iron stores so that hyperferri-
tinemia indicates unregulated L-ferritin synthesis, not
iron overload. Although in HHCS L-ferritin may accu-
mulate harmlessly in other tissues, this is not the case in
the lens of the eye, where low protein turnover and con-
tainment by the capsule may retain ferritin synthesized
within the lens; accumulated ferritin crystals may then
disrupt light transmission.
HHCS is associated with bilateral cataracts, autosomal
dominant inheritance, and hyperferritinemia unrelated
to body iron stores. Although HHCS is increasingly rec-
ognized as a clinical syndrome, other published reports
indicate that the diagnosis is often missed initially and
only recognized following the adverse effects of venesec-
tion or chelation therapy with desferrioxamine.3 This is
well illustrated in the present patient in whom there
were several missed opportunities for exclusion of hemo-
chromatosis and diagnosis of HHCS. These include:
Fig. 1. (A) Pedigree show-
ing autosomal dominant
inheritance of hyperferritine-
mia with cataracts. Solid
symbol, affected; open sym-
bol, unaffected, gray symbol,
unknown; arrow, proband (P).
(B) Sequence chromatogram
of the FTL gene from the pro-
band (upper panel) and his
mother (lower panel), showing
the heterozygous c.-160A>G
mutation (arrow; Reference
Sequence NM_000146.3).
(C) IRE prediction of wild-type
FTL mRNA showing the muta-
tion site (arrow) in the apical
loop which binds IRPs. Bioinfor-
matic analysis of c.-160A>G
mutant FTL did not predict an
IRE. (D) Schematic diagram
showing how the c.-160A>G
mutation causes loss of nor-
mal IRE-IRP-mediated repres-
sion of FTL expression at low
intracellular iron concentra-
tions, causing unregulated
L-ferritin synthesis, in the
absence of iron overload, in
HHCS.
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family screening (at presentation of the grandmother
and mother as well as the patient); at interpretation of
the liver biopsy histopathology result showing no iron
overload; at rheumatological investigation of this
young patient with rheumatoid factor negative arthri-
tis. For the serum biochemical investigation of iron
status, along with measurement of ferritin concentra-
tion, iron concentration, and TIBC for determination
of transferrin saturation are always required. In this
case, despite venesection and the development of iron
deficiency, serum ferritin remained persistently elevated
in the absence of iron overload. Hemochromatosis
cannot be diagnosed on the grounds of hyperferritine-
mia without iron overload.
There are other causes of hyperferritinemia without
evidence of iron overload, including alcohol abuse,
obesity, inflammation, and occult malignancy. In those
without these causes who are not homozygous for
HFE p.(C282Y), a strong case can be made for oph-
thalmological investigation and screening for mutations
in SLC40A1 and the IRE of FTL. Clearly, an aware-
ness of the existence of HHCS is essential but, until
consensus guidelines covering this scenario are devel-
oped, screening as outlined above will avoid misdiag-
nosis of the syndrome and so prevent unnecessary liver
biopsy and the consequences of unwarranted
treatment.
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